Disease Progression Modeling for Economic Evaluation in Nonalcoholic Fatty Liver Disease —A Systematic Review

Globally, 25% of people have nonalcoholic fatty liver disease (NAFLD), and, currently, there are no approved pharmacologic treatments for NAFLD. With a slow disease progression, long-term impact of pharmacologic treatments can be assessed only by complementing emerging clinical trial evidence with data from other sources in disease progression modeling. Although this modeling is crucial for economic evaluation studies assessing the clinical and economic consequences of new treatments, the approach to modeling the natural history of NAFLD differs in contemporary research.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Source Type: research